Andrew D. Leavitt, MD is the director of UCSF’s program for nonmalignant (classical) hematology and the medical director of the UCSF Adult Hemophilia Treatment Center. He cares for patients with classical/nonmalignant blood diseases, including bleeding disorders (such as hemophilia and von Willebrand disease), platelet function disorders, disorders of insufficient platelets (such as immune thrombocytopenia and thrombotic thrombocytopenic purpura), venous thromboembolic disorders (blood clots), neutropenia (reduced numbers of the white blood cells called neutrophils) and anemia. His current research focuses on improving treatment and outcomes for patients with bleeding disorders and venous thromboembolic diseases. He is internationally known for his prior studies of the development of megakaryocytes, large cells in the bone marrow that produce circulating platelets.

Dr. Leavitt obtained his medical degree at Harvard Medical School. He completed an internal medicine residency and served as chief resident at the University of Michigan. At UCSF, he completed a fellowship in hematology and oncology, followed by a fellowship in transfusion medicine. He joined the UCSF faculty in 1992.

Dr. Leavitt has served on expert guideline panels for venous thromboembolism treatment in patients with cancer. He has also served on the editorial boards of the journal Blood, the Journal of Clinical Investigation, and the Journal of Clinical and Translational Science. He currently is the site principle investigator on a number of clinical research trials aimed at advancing the care of patients with bleeding disorders.